

J Michael Kilby

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8723225/publications.pdf>

Version: 2024-02-01

49
papers

9,316
citations

201674

27
h-index

214800

47
g-index

155
all docs

155
docs citations

155
times ranked

8740
citing authors

#	ARTICLE	IF	CITATIONS
1	Antibody neutralization and escape by HIV-1. <i>Nature</i> , 2003, 422, 307-312.	27.8	2,233
2	Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 7552-7557.	7.1	1,708
3	Emergence of Resistant Human Immunodeficiency Virus Type 1 in Patients Receiving Fusion Inhibitor (T-20) Monotherapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 1896-1905.	3.2	1,483
4	Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. <i>Nature Medicine</i> , 1998, 4, 1302-1307.	30.7	985
5	Initial increase in blood CD4+ lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. <i>Journal of Clinical Investigation</i> , 1999, 103, 1391-1398.	8.2	293
6	Novel Therapies Based on Mechanisms of HIV-1 Cell Entry. <i>New England Journal of Medicine</i> , 2003, 348, 2228-2238.	27.0	243
7	SIVcpz in Wild Chimpanzees. <i>Science</i> , 2002, 295, 465-465.	12.6	207
8	Constant Mean Viral Copy Number per Infected Cell in Tissues Regardless of High, Low, or Undetectable Plasma HIV RNA. <i>Journal of Experimental Medicine</i> , 1999, 189, 1545-1554.	8.5	195
9	The Safety, Plasma Pharmacokinetics, and Antiviral Activity of Subcutaneous Enfuvirtide (T-20), a Peptide Inhibitor of gp41-Mediated Virus Fusion, in HIV-Infected Adults. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 685-693.	1.1	187
10	A Multicenter Observational Study of the Potential Benefits of Initiating Combination Antiretroviral Therapy during Acute HIV Infection. <i>Journal of Infectious Diseases</i> , 2006, 194, 725-733.	4.0	163
11	Modeling sequence evolution in acute HIV-1 infection. <i>Journal of Theoretical Biology</i> , 2009, 261, 341-360.	1.7	162
12	Sex, Race, and Geographic Region Influence Clinical Outcomes Following Primary HIV-1 Infection. <i>Journal of Infectious Diseases</i> , 2011, 203, 442-451.	4.0	149
13	Short-Term Safety and Antiretroviral Activity of TMC1249, a Second-Generation Fusion Inhibitor of HIV. <i>Journal of Infectious Diseases</i> , 2004, 189, 1075-1083.	4.0	132
14	A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. <i>Aids</i> , 2003, 17, 691-698.	2.2	130
15	Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 4512-4517.	7.1	126
16	Safety and Pharmacokinetics of Once-Daily Regimens of Soft-Gel Capsule Saquinavir plus Minidose Ritonavir in Human Immunodeficiency Virus-Negative Adults. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 2672-2678.	3.2	92
17	Gender Differences in Discontinuation of Antiretroviral Treatment Regimens. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 52, 336-341.	2.1	86
18	A Randomized, Partially Blinded Phase 2 Trial of Antiretroviral Therapy, HIV-Specific Immunizations, and Interleukin-2 Cycles to Promote Efficient Control of Viral Replication (ACTG A5024). <i>Journal of Infectious Diseases</i> , 2006, 194, 1672-1676.	4.0	78

#	ARTICLE	IF	CITATIONS
19	Delayed access to HIV diagnosis and care: Special concerns for the Southern United States. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2006, 18, 35-44.	1.2	56
20	Recurrence of the Acute HIV Syndrome after Interruption of Antiretroviral Therapy in a Patient with Chronic HIV Infection: A Case Report. <i>Annals of Internal Medicine</i> , 2000, 133, 435.	3.9	55
21	Factors Associated with Delayed Initiation of HIV Medical Care Among Infected Persons Attending a Southern HIV/AIDS Clinic. <i>Southern Medical Journal</i> , 2006, 99, 472-481.	0.7	54
22	HIV-1 and HAART: A time to cure, a time to kill. <i>Nature Medicine</i> , 1999, 5, 609-611.	30.7	50
23	CD8 T-cell responses in early HIV-1 infection are skewed towards high entropy peptides. <i>Aids</i> , 2005, 19, 241-50.	2.2	41
24	Enfuvirtide. <i>Expert Opinion on Investigational Drugs</i> , 2002, 11, 1837-1843.	4.1	36
25	Correlation between Circulating Stromal Cell-Derived Factor 1 Levels and CD4+ Cell Count in Human Immunodeficiency Virus Type 1-Infected Individuals. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 1063-1071.	1.1	35
26	The Virologic and Immunologic Effects of Cyclosporine as an Adjunct to Antiretroviral Therapy in Patients Treated during Acute and Early HIV-1 Infection. <i>Journal of Infectious Diseases</i> , 2010, 201, 1298-1302.	4.0	33
27	The Virologic, Immunologic, and Clinical Effects of Interleukin 2 With Potent Antiretroviral Therapy in Patients With Moderately Advanced Human Immunodeficiency Virus Infection. <i>Archives of Internal Medicine</i> , 2007, 167, 597.	3.8	30
28	Treatment response in acute/early infection versus advanced AIDS: equivalent first and second phases of HIV RNA decline. <i>Aids</i> , 2008, 22, 957-962.	2.2	22
29	Safety, tolerability, and plasma pharmacokinetics of high-strength formulations of enfuvirtide (T-20) in treatment-experienced HIV-1-infected patients. <i>Journal of Clinical Virology</i> , 2004, 30, 183-190.	3.1	21
30	Humoral immune responses to <i>Streptococcus pneumoniae</i> in the setting of HIV-1 infection. <i>Vaccine</i> , 2015, 33, 4430-4436.	3.8	21
31	Perspectives on inducing efficient immune control of HIV-1 replication - a new goal for HIV therapeutics?. <i>Aids</i> , 2001, 15, S36-S42.	2.2	20
32	Cost-Effectiveness of Enfuvirtide in HIV Therapy for Treatment-Experienced Patients in the United States. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 240-247.	1.1	20
33	Functionally Competent Antigen-Specific CD127hi Memory CD8+ T Cells Are Preserved Only in HIV-1-Infected Individuals Receiving Early Treatment. <i>Journal of Infectious Diseases</i> , 2007, 195, 108-117.	4.0	20
34	Pathological Role of Anti-CD4 Antibodies in HIV-Infected Immunologic Nonresponders Receiving Virus-Suppressive Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2017, 216, 82-91.	4.0	20
35	<i>Actinomyces meyeri</i> , a Common Agent of Actinomycosis. <i>American Journal of the Medical Sciences</i> , 2016, 352, 53-62.	1.1	16
36	Use of an Outreach Coordinator to Reengage and Retain Patients with HIV in Care. <i>AIDS Patient Care and STDs</i> , 2017, 31, 222-226.	2.5	16

#	ARTICLE	IF	CITATIONS
37	Plasmacytoid Dendritic Cells Mediate Synergistic Effects of HIV and Lipopolysaccharide on CD27 ⁺ IgD ⁺ Memory B Cell Apoptosis. <i>Journal of Virology</i> , 2014, 88, 11430-11441.	3.4	14
38	Human Immunodeficiency Virus Pathogenesis: Insights from Studies of Lymphoid Cells and Tissues. <i>Clinical Infectious Diseases</i> , 2001, 33, 873-884.	5.8	13
39	CD8 T-Cell Proliferative Capacity Is Compromised in Primary HIV-1 Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 56, 213-221.	2.1	13
40	Key differences in B cell activation patterns and immune correlates among treated HIV-infected patients versus healthy controls following influenza vaccination. <i>Vaccine</i> , 2016, 34, 1945-1955.	3.8	13
41	Therapeutic potential of blocking HIV entry into cells: focus on membrane fusion inhibitors. <i>Expert Opinion on Investigational Drugs</i> , 1999, 8, 1157-1170.	4.1	11
42	Switching HIV therapies: competing host and viral factors. <i>Lancet, The</i> , 2010, 375, 352-354.	13.7	6
43	Prolonged Suppression of Human Immunodeficiency Virus Type 1 RNA during Dual Nucleoside Reverse Transcriptase Inhibitor Therapy in Clinical Practice. <i>Clinical Infectious Diseases</i> , 2000, 31, 1095-1097.	5.8	3
44	The induction of CD80 and apoptosis on B cells and CD40L in CD4+ T cells in response to seasonal influenza vaccination distinguishes responders versus non-responders in healthy controls and aviremic ART-treated HIV-infected individuals. <i>Vaccine</i> , 2017, 35, 831-841.	3.8	3
45	Therapeutic immunization strategies for HIV infection. <i>Current Opinion in HIV and AIDS</i> , 2006, 1, 74-81.	3.8	2
46	Cytomegalovirus Esophageal Ulcers. <i>New England Journal of Medicine</i> , 2000, 342, 475-475.	27.0	0
47	Salmonella Infections in the Setting of AIDS: A Serpentine Course. <i>Southern Medical Journal</i> , 2005, 98, 1066-1067.	0.7	0
48	Future clinical prospects for entry inhibitors. , 2007, , 145-160.		0
49	Microbial TLR Agonists and Humoral Immunopathogenesis in HIV Disease. <i>Epidemiology (Sunnyvale, Calif)</i> 2014;25(1):103-114. doi:10.1093/epidem/kft144	0.3	0